The decline in the PCLN stock price has created a buying opportunity, as Wall St. overreacts to Priceline's lower earnings guidance. More
With Netflix, Inc., a Negative Is a Sign of Good Things
In Netflix speak, that means you keep spending on content until you stop growing the number of members, revenue and profits. That’s not happening and so it continues to invest in new content. More
Bristol-Myers Squibb Co (BMY) Industry Group Rank Penalize Rating
Bristol-Myers Squibb Co (NYSE:BMY) is a $103.5 billion in market value constituent of the Pharmaceuticals GICS industry group where Portfolio Grader's current ranking for BMY puts it 64 among the 134 companies in this industry group, placing it in the top half. BMY is ranked in the top half of the sector with a ranking of 370 among the 782 companies in the sector and number 2,185 in the 5000 company Portfolio Grader company universe. More
Is Tax Reform Already Priced In?
With the S&P 500 near its all-time high, it’s hard to make the argument that some of the anticipated impacts of tax reform aren't already priced into the market. More
Sanofi (SNY) a Hold on Vapid Earnings Momentum
Sanofi SA (NYSE:SNY) is a constituent of the 134 company Pharmaceuticals GICS industry group, which is a segment of the 782 company GICS Health Care sector. SNY's market value is $112.1 billion which places it in the top 10% of its industry group. Portfolio Grader's current ranking for SNY puts it 53 among the 134 companies in this industry group, placing it in the top half; in the top half of the sector with a ranking of 307 among the 782 companies in the sector, and number 1,707 in the nearly 5,000 company Portfolio Grader universe. More
You Should Buy Square Inc Today
If you believe the bullish narrative in SQ stock, the time is now to go long in Square, but with a bit more safety. More
